Medic Claims These Three Diseases Will Be Gone By 2030 — Illness No. 1 Kills 3 In Every 5 Indians
A surprising medical claim has caught attention after a medical student from Budapest revealed that cancer, blindness and paralysis could be "fully eradicated by 2030".
Medical science has advanced to a point where curing some of the most dangerous illnesses is no longer just a dream. It now appears we may be only a few steps away from completely eradicating them. A surprising claim has recently gained attention after a medical student from Budapest announced that 'cancer, blindness, and paralysis could be fully eliminated by 2030". According to this digital creator, scientists worldwide are employing advanced vaccines, modern treatments, and cutting-edge technologies to combat these conditions.
Big Hope For Deadly Diseases
According to the medical student, Chris Chrysanthou, 'Here are three diseases that are expected to be completely eradicated by 2030. Number one, cancer. Forget chemo, researchers are now using mRNA cancer vaccines to train your immune system to attack tumours like an army. Personalised vaccines, genetic editing and even small drugs are in the final testing stages. With many experts believing that cancer might soon be treatable, manageable and no longer deadly."
'Number two, blindness. Thanks to gene editing and stem cells, patients with retinal diseases are regaining sight. Projects in already helped two blind patients see again, and a new tech called prime editing could fix the genetic mutations causing inherited blindness. Number three, paralysis. In China, two people with full paralysis walked again using a combo of brain implants and spinal cord stimulation. The brain literally sent signals directly to the legs, bypassing the spinal injury," the medical student added.
Internet Shares Mixed Reactions
Reacting to the post, a user wrote, 'Science is such a wonderful thing."
Another shared, 'As long as the pharmaceutical industry makes money and the cancer industry makes money. It will never be a cure for cancer. It is too lucrative. I wish that were true, but in America, only money rules."
'If they can cure blindness by 2030, will they also cure nearsightedness and farsightedness using those same gene therapy & stem cells?!? Ridding myself of eye doctor appointments would be a miracle," a comment read.
An individual stated, 'Diabetes, too. Researchers in China have found a way to cure Diabetes."
Another mentioned, 'I thought you were gonna mention HIV cause there's been some word that the cure is very near with successful data."
One more added, 'Let's hope it becomes available and affordable to the masses and those who really need it."
Cancer Rate In India
Recent cancer data plays a crucial role in planning strategies to control, treat, and reduce the disease's impact. A study titled Unveiling the Cancer Epidemic in India: A Glimpse into GLOBOCAN 2022 and Past Patterns, published in The Lancet, examined cancer incidence and mortality in India using data from The Global Cancer Observatory (GLOBOCAN) 2022.
The report highlights cancer as a major health concern in India, placing the country third worldwide in total cancer cases, second in cancer-related deaths, and 121st in global crude rates. The likelihood of developing cancer rises with age, particularly among older adults. The study analysed the disease's impact across different age groups and corresponding mortality rates, while also projecting future cases based on historical trends. It found that children and young adults face the lowest risk, whereas middle-aged and older individuals have the highest probability of both developing cancer and dying from it.
view comments
Location :
Delhi, India, India
First Published:
August 12, 2025, 08:05 IST
News viral Medic Claims These Three Diseases Will Be Gone By 2030 — Illness No. 1 Kills 3 In Every 5 Indians
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
9 hours ago
- Time of India
Lab-grown rabies antibodies show promise as cheaper, safer alternative
Mumbai: India's public hospitals and dispensaries may soon have a safer, more affordable option for preventing rabies after a suspected rabid dog bite: one already in use in private clinics since 2017 and by BMC since 2019. A post-marketing clinical trial involving more than 4,000 participants, conducted and funded by a pharmaceutical company and recently published in The Lancet, could now pave the way for its large-scale public use. For decades, the life-saving protocol has been the same across public or private health set ups: wash the wound, inject a dose of rabies immunoglobulin if the bite is severe, and follow with multiple doses of anti-rabies vaccine. The possible shift lies in the kind of immunoglobulin used. The relatively new lab-made candidate could replace the animal and human derived versions in use since the 1970s. An immunoglobulin is a concentrated solution of antibodies, injected directly into and around the bite, that offers immediate but short-term protection against the virus, effectively buying time until the vaccine takes full effect. The earliest ones in use have been derived either from rabies-vaccinated horses (Equine Rabies Immunoglobulin - ERIG) or human donated plasma (Human Rabies Immunoglobulin - HRIG). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo In 2016, Serum Institute of India (SII) received permission to make immunoglobulin which has monoclonal (lab-made,RmAb) antibodies. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai | Gold Rates Today in Mumbai | Silver Rates Today in Mumbai "Most private facilities at least in Mumbai have phased out the use of the horse-derived one. While it has been proven safe at large, there are risks associated; it can cause mild allergic reactions or in rare cases a serious adverse event," said Dr Trupti Gilada, city-based infectious disease specialist. The private facilities have moved on to either the human derived or lab-made ones. "Both, human derived one and the lab-made one have high efficacy. The former has risk of infection transmission, though rare. The ones made in labs are safer and more easily available due to ease of largescale production," said Dr Mandar Kubal, another infectious disease specialist. A survey by ICMR published in July on the availability of anti-rabies vaccine and rabies immunoglobulin in health facilities found that, of the 534 facilities surveyed across 15 states and 60 districts -- 467 in the public sector -- 78% still used horse derived immunoglobulin. But even that was out of stock for most apart from a small 20.3% of those surveyed. While BMC uses the lab-made alternative, it is no stranger to shortages; at the moment it is short of rabies vaccine shots. A senior doctor from one of the four BMC-run medical college hospitals, said, "Mumbai has a heavy burden of dog bite cases and early on BMC decided to move on from animal derived ones due to risks associated. We either use generic human derived immunoglobulin or largely lab-made alternatives." But this lab-made alternative is still to make its way into the National Guidelines for Rabies Prophylaxis. The ICMR survey states, "RmAb presents as a promising alternative to both HRIG and ERIG. Compared to ERIG, RmAb offers the potential scope for large-scale production with standardised quality, elimination of animal use in the manufacturing, and reduced risk of adverse events. "It is cheaper compared to HRIG. Studies have shown that RmAbs are safe for human use, but... [there is] need for larger clinical trials and post-marketing surveillance to assess the safety and efficacy of RmAbs in the Indian setting." The Serum Institute–funded post marketing trial of its lab-made product compared with horse-derived immunoglobulin found to be equally effective in preventing rabies, with slightly higher average antibody levels on day 14. It was linked to fewer mild adverse events (11 vs. 17), and no serious reactions related to RmAb were reported, compared with one serious reaction related to ERIG. "Anti-rabies vaccines and immunoglobulins are severely in shortage across the country. Monoclonal antibodies is the answer [due to scalability] and it needs to be included in the national guidelines," said one of the authors of the ICMR survey. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Time of India
10 hours ago
- Time of India
Lab-grown rabies antibodies show promise as safe alternative
MUMBAI: India's public hospitals and dispensaries may soon have a safer, more affordable option for preventing rabies after a suspected rabid dog bite: one already in use in private clinics since 2017 and by BMC since 2019. Tired of too many ads? go ad free now A post-marketing clinical trial involving more than 4,000 participants, conducted and funded by a pharmaceutical company and recently published in The Lancet, could now pave the way for its large-scale public use. For decades, the life-saving protocol has been the same across public or private health set ups: wash the wound, inject a dose of rabies immunoglobulin if the bite is severe, and follow with multiple doses of anti-rabies vaccine. The possible shift lies in the kind of immunoglobulin used. The relatively new lab-made candidate could replace the animal and human derived versions in use since the 1970s. An immunoglobulin is a concentrated solution of antibodies, injected directly into and around the bite, that offers immediate but short-term protection against the virus, effectively buying time until the vaccine takes full effect. The earliest ones in use were derived either from rabies-vaccinated horses (Equine Rabies Immunoglobulin - ERIG) or human donated plasma (Human Rabies Immunoglobulin - HRIG). In 2016, (SII) received permission to make immunoglobulin which has monoclonal (lab-made,RmAb) antibodies. "Most private facilities at least in Mumbai have phased out the use of the horse-derived one. While it has been proven safe at large, there are risks associated; it can cause mild allergic reactions or in rare cases a serious adverse event," said Dr Trupti Gilada, city-based infectious disease specialist. The private facilities have moved on to either the human derived or lab-made ones. "Both, human derived one and the lab-made one have high efficacy. Tired of too many ads? go ad free now The former has risk of infection transmission, though rare. The ones made in labs are safer and more easily available due to ease of largescale production," said Dr Mandar Kubal, another infectious disease specialist. A survey by ICMR published in July on the availability of anti-rabies vaccine and rabies immunoglobulin in health facilities found that, of the 534 facilities surveyed across 15 states and 60 districts -- 467 in the public sector -- 78% still used horse derived immunoglobulin. But even that was out of stock for most apart from a small 20.3% of those surveyed. While BMC uses the lab-made alternative, it is no stranger to shortages; at the moment it is short of rabies vaccine shots. A doctor from one of the four BMC-run medical college hospitals, said, "Mumbai has a heavy burden of dog bite cases and early on BMC decided to move on from animal derived ones due to risks associated. We either use generic human derived immunoglobulin or largely lab-made alternatives." But this lab-made alternative is still to make its way into National Guidelines for Rabies Prophylaxis. The ICMR survey states, "RmAb presents as a promising alternative to both HRIG and ERIG. Compared to ERIG, RmAb offers the potential scope for large-scale production with standardised quality, elimination of animal use in the manufacturing, & reduced risk of adverse events. "It is cheaper compared to HRIG. Studies have shown that RmAbs are safe for human use, but... [there is] a need for larger clinical trials and post-marketing surveillance to assess the safety and efficacy of RmAbs in the Indian setting." The Serum Institute-funded post marketing trial of its lab-made product compared with horse-derived immunoglobulin found to be equally effective in preventing rabies, with slightly higher average antibody levels on day 14.
Indian Express
a day ago
- Indian Express
CM Manik Saha warns students about HIV, substance abuse; says Tripura saw 103% rise in drug seizures in 2023-24
Expressing concern about drug abuse and the spread of HIV in the Northeast, including Tripura, Chief Minister Dr Manik Saha Tuesday said the state witnessed a steep rise of 103 per cent in drug seizures, while the destruction of seized drugs also saw an increase of 130 per cent in 2023-24. Speaking about HIV at a state-level programme titled 'Bell of Awareness' at Pragna Bhawan in Agartala on the occasion of International Youth Day, Saha said, 'At present, Tripura ranks fourth in the (Northeast) region.' Currently, the state government provides a monthly pension of Rs 2,000 to 3,433 HIV-positive individuals. Warning students about how drug addiction does not happen overnight but gradually, he said, 'You (students) must be cautious when it comes to drugs. Parents should pay special attention. Prime Minister Narendra Modi-ji and Union Home Minister Amit Shah-ji laid emphasis on building a nashamukt Bharat (drug-free India). Our government is also following a zero-tolerance policy on drugs to make Tripura nashamukt.' 'But it is not possible only with the efforts of the state government or any department. In this case, all sections of society are required to come forward to combat HIV/AIDS,' the chief minister said while urging to expand the activities of Red Ribbon Clubs in schools and colleges to combat the infection. At least 6,000 students from across the state attended the event. Saha said the state government is also thinking about spreading awareness in schools about HIV/AIDS and the dangers of drug abuse by incorporating it in the curriculum. According to the Health and Family Welfare department, Tripura reported having 1,845 people with HIV during the 2022-23 period, 1,790 people in 2023-24, and 1,185 in 2024-25 (till January this year). In January this year, Saha said that according to the National AIDS Control Organisation's (NACO) estimation report of 2023, Tripura saw 1.12 AIDS-related deaths for every 1 lakh unaffected people in 2021 – a figure that reduced to 0.99 in 2022 but again rose to 1.08 in 2023. Initiatives adopted by the state government to increase awareness about HIV include district-level sensitisation programmes involving the principals of 220 schools where drug abuse through injections was identified, an integrated health campaign in West Tripura district to identify cases of HIV, Hepatitis B, Hepatitis C, syphilis in vulnerable groups, and using LED screens at 21 locations across Tripura to display messages related to HIV/AIDS and drug abuse through injections as part of a mass awareness campaign in January this year.
